scholarly journals Drug use and pregnancy – challenges for public health

2009 ◽  
Vol 14 (9) ◽  
Author(s):  
V A Gyarmathy ◽  
I Giraudon ◽  
D Hedrich ◽  
L Montanari ◽  
B Guarita ◽  
...  

Problem drug use in pregnancy affects a sizeable population in Europe. A literature review was carried out of articles in PubMed, European Monitoring Centre for Drugs and Drug Addiction publications, and related documents in order to assess public health challenges and possible intervention strategies related to problem drug use and pregnancy in Europe. It revealed the following: Involving pregnant drug users in drug treatment is likely to decrease the chances of pre- and perinatal complications related to drug use and to increase access to prenatal care. Timely medical intervention can effectively prevent vertical transmission of human immunodeficiency virus, hepatitis B virus as well as certain other sexually transmitted diseases, and would allow newborns infected with hepatitis C virus during birth to receive immediate treatment. Pregnancy may be a unique opportunity to also help women with dual diagnosis (substance use combined with mental illness) and enrol them into special treatment and support programmes. Issues related to homelessness and intimate partner violence can also be addressed with appropriate interventions. Treatment and care for pregnant drug users should offer coordinated interventions in several areas: drug use, infectious diseases, mental health, personal and social welfare, and gynaecological/obstetric care.

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  

Abstract According to the latest data, in 2018 about 590,000 people were held in prison on any given day in the EU, and more than double in the entire region. People in prison face multiple and complex health care issues, including a higher prevalence of communicable diseases than the general population. These are likely to be the result of a combination of overlapping, and sometimes interlinked, risk factors for infection, ill-health, and incarceration, such as problem drug use. Incarceration may facilitate the offer of quality health care services to people who are otherwise hard to reach and provide an occasion to target socially deprived groups who often have low level of healthcare access when in the community. Delivering health protection and harm reduction programmes in prisons not only benefits the prison population but also has the potential to reduce the risk of transmission of some infectious diseases in the community, intervening earlier in the natural history of disease. They are also likely also to have a knock-on effect in supporting individuals’ reintegration into community life and future health - providing a ‘community dividend’ to health interventions in prisons. Yet, such health gains may be diminished by suboptimal integration with community services. Continuity of care, or throughcare, between prison and community services is a mainstay of any health care interventions delivered in detention, especially when tackling chronic conditions (e.g. HIV, mental illnesses) or problem drug use. The World Health Organization (WHO) has long supported the concept of prison health as an inseparable component of public health. This view is enshrined by the principle of Equivalence of Care between prison and community, endorsed by the United Nations in the Nelson Mandela Rules. During the 2019 WHO Prison Health Conference in Helsinki, it was acknowledged that prisons contribute to achieving the UN’s Sustainable Development Goals through improving health, reducing health inequalities and provide a fairer and safer society for all. However, a number of challenges hampers the successful implementation of such a concept, including the need for evidence-based decision making, inter-sectoral partnerships and adequate monitoring systems. This workshop will provide attendees with a comprehensive overview of prison health and the relevance of a multi-sectorial public health approach to frame and address it. The workshop will be structured around three main topics: governance of prison health and current models in Europe; health issues and disease burden in the prison population; current and future perspectives for evidence-based approaches to prison health. The discussion of two case studies, problem drug use and HCV micro-elimination, will create the context for an in-depth analysis of key challenges for prison health implementation, reflecting on aspects such as health needs, equity, multidisciplinarity, continuity of care, monitoring and community dividend. Key messages Provide a comprehensive picture of the main challenges of prison health in Europe, the public health issues affecting the prison population and how these relate to community public health systems. Reflect on how public health systems need to incorporate prison health into their strategies for reducing inequalities and improving health outcomes of vulnerable and socially deprived populations.


2019 ◽  
Vol 25 (3) ◽  
pp. 421-437 ◽  
Author(s):  
Clay Darcy

The purpose of this article is to explore the motivations behind some men’s recreational use of illicit drugs from a gender standpoint. The rationale for this analysis stems from men’s predominance as illicit drug users and their likelihood of experiencing problem drug use and becoming a part of an over-represented population in drug treatment services. Explanations for men’s problematic/addicted patterns of drug use often point to marginalisation, disadvantage, and/or men’s tendency towards problematic health behaviours. This article argues that men’s illicit recreational drug use is often glossed over as a gendered activity and receives less scrutiny than problematic/addicted patterns of drug taking. It examines the drug-taking motivations of 20 Irish men who identified as illicit recreational drug users to expand on and deepen current explanations for men’s illicit recreational drug use. The article demonstrates how men engage in drug use for complex and contradictory reasons that include embodied quests for pleasure and excitement, achieving connection with other men, and performing or contravening masculinities in homosocial contexts.


Medicina ◽  
2011 ◽  
Vol 47 (6) ◽  
pp. 48 ◽  
Author(s):  
Audronė Astrauskienė ◽  
Valerij Dobrovolskij ◽  
Rimantas Stukas

The aim of this study was to estimate and assess the prevalence of problem drug use in Lithuania. Materials and Methods. The capture-recapture method was used to estimate the prevalence of problem drug use. For the study, the data concerning problem drug users were collected from the databases of health care and law enforcement institutions. The target group consisted of permanent users (aged 15–64 years) of heroin and other opioids and/or a combination of drugs. Results. In Lithuania, 431 monitored problem drug users were identifi ed in 2005, 482 in 2006, and 447 in 2007. The male-to-female ratio among the monitored problem drug users was 6:1 in 2006 and 4:1 in 2005 and 2007. The mean age of the monitored problem drug users was 26.8 years in 2005, 27.6 years in 2006, and 28.0 years in 2007. In total, 5699 problem drug users were identified (95% CI, 5552 to 5849) in 2005, 5800 (95% CI, 5652 to 5951) in 2006, and 5458 (95% CI, 5314 to 5605) in 2007. According to the gathered data, the prevalence of problem drug use was 2.3 cases per 1000 Lithuanian population aged 15–64 years in 2005, 2.5 in 2006, and 2.4 in 2007. Conclusions. The study showed one of the lowest prevalence of problem drug use in Lithuania as in Germany, the Netherlands, Greece, and Cyprus. In 2005–2007, problem drug users were mainly young men of employable age in Lithuania.


2005 ◽  
Vol 22 (3-4) ◽  
pp. 197-208
Author(s):  
Sturla Nordlund

■ Aims The aim is to describe the development of the availability, attitudes to, and personal use of illegal drugs among the adult population in Norway, based on survey data from 1968 until today. Compared with data on young people, the data on drugs for the adult population have been collected more rarely, and results have not been widely reported. ■ Data and Method Surveys directed to the adult population with questions about drugs were performed in 1968, 1985, 1991, 1994, 1999 and 2004. The samples are selected in a three stage stratified quota procedure, and are representative for the whole adult population age 15 years and over. The data were collected with a face-to-face interview, mainly about alcohol. The drug questions were answered in writing, and in such a way that the interviewer did not see the answers. The availability of all kinds of drugs was measured by asking if the respondents think they could get hold of it in 2–3 days. ■ Results The availability of drugs has increased. In 2004, some 35 per cent said they could get hold of cannabis, while some 20 per cent could get other drugs. The attitudes towards own use were measured by asking if the respondents would try the drugs if it was not illegal. In 2004 about 8 per cent were positive about trying cannabis, with less than 2 per cent for all the other drugs. The attitudes have not varied much for any of the drugs between 1994 and 2004 and for cannabis have been rather stable since 1968. Lifetime prevalence of cannabis use has increased continuously since 1968, and was about 13.5 per cent in 2004. Last year prevalence increased until 1994, but has stabilised at about 3.7 per cent since then. For other drugs the lifetime prevalence has been stable at less than 2 per cent, with around 3 per cent for amphetamines. Last year, the prevalence of these drugs was less than 1 per cent, possibly with a slightly decreasing tendency. For cannabis the highest prevalence (both lifetime, previous year, and previous 30 days) is in the age group 20–24 years. ■ Conclusion The results are somewhat contrary to reports about increased problematic drug use in Norway during the 1990s. Survey methods are however not the best method to estimate problem drug use. The stability and even tendency to decrease of the prevalence of present drug use shown here might, however, indicate a decrease in the recruitment of problem drug users. Other signs point in the same direction: The sharp increase in drug-related deaths in Norway during the 1990s has given way to a decrease in the latest years. The prevalence of present drug use in youth surveys shows a decreasing trend.


1988 ◽  
Vol 152 (2) ◽  
pp. 214-221 ◽  
Author(s):  
Julie Parker ◽  
Yvonne Pool ◽  
Robert Rawle ◽  
Martyn Gay

A prospective multi-agency survey of problem drug use associated with illicit drugs and solvents in the city of Bristol in 1984–1985 found 759 problem drug users, giving a period prevalence rate of 0.4–0.8% of those aged 10–44 years. The group was a young one, with 92% under the age of 35. Over half had problems associated with opiates, mainly illicit heroin; 17% had problems associated with solvents, 9% with cannabis, 13% with stimulants, mainly illicit amphetamine, and 3% with hallucinogens. There was little indication of problematic use of barbiturates or cocaine. The problems associated with drugs and solvents were wide-ranging and not specific for individual drugs. Future community surveys would find it cost-effective to concentrate on the five best sources identified here, and to supplement these with indications of drug-taking among teenagers. The difficulties of using the definition of problem drug use for research and the value of case-register surveys for community drug monitoring are discussed.


Sign in / Sign up

Export Citation Format

Share Document